Pioneering Next-Generation
Antibodies for
Autoimmune Diseases.

Our Story

Omni Biotech Innovations is a Canadian based, early-stage drug discovery company focused on developing differentiated antibodies for the treatment of autoimmune diseases. Our mission is deeply rooted in our passion for bringing safe and effective medicines to Autoimmune disease patients with the greatest unmet needs. We leverage validated targets to create bi & multi-specific antibody therapeutics through innovative antibody engineering, with an aim to develop “best-in-class" antibody therapies. Our team is composed of experienced scientific founders with complementary expertise in antibody engineering, immunology, BD, and drug development.

Autoimmune Disease


Autoimmune diseases represent a large (~$120B) yet underserved and underinvested market with very low penetration for antibodies. Current therapies suffer from low remission rates and serious side effects, creating a demand for more targeted and effective treatment options. While bispecific & multi-specific antibody approaches have shown promise in cancer treatment, they remain under-explored in autoimmune disorders, presenting a unique opportunity for us. Recognizing this, we’ve chosen to focus on developing bispecific & multi-specific antibody therapies to address this critical gap.

Autoimmune Disease Conceptual Image

Our Business Model

We accelerate early-stage drug discovery and development by combining in-house research with strategic collaborations. We begin with a clear product concept and then strategically integrate validated intellectual property pieces, such as proven antibody fragments, to develop our products and achieve clinical validation in patients at a reduced cost.

Innovation Funnel
Collaboration Funnel
Integration Funnel

Our Science

Built on Omni Biotech's proprietary platform & developed in collaboration with our partners, OBTI001 targets the root cause of autoimmunity to improve patient outcomes and enable effective long-term disease management. OBTI001 is a novel multi-specific antibody therapy which selectively targets multiple B-cell populations and different receptor molecules using one drug. With the potential to treat a range of diseases—from more prevalent conditions like Rheumatoid Arthritis to rare diseases such as Sjogren's Syndrome and Myasthenia Gravis—OBTI001 offers a "pipeline in a product" market opportunity.

Our Pipeline

ASSET
TARGET
CONCEPT
LEAD OPTIMIZATION
IND ENABLING
PHASE 1
OBTI001
B-cell Targets
OBTI002
Undisclosed

Our Team